John Overdeck’s Insight Molecular Diagnostics IMDX Stock Holding History

John Overdeck’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.5K	Buy	+11,101	New	+$54.8K	﹤0.01%	4931
2022 Q1	–	Sell	-8,115	Closed	-$352K	–	3828
2021 Q4	$352K	Sell	8,115 -19,551	-71%	-$1.12M	﹤0.01%	3532
2021 Q3	$1.97M	Buy	27,666 +810	+3%	+$74.5K	﹤0.01%	2006
2021 Q2	$3.08M	Buy	26,856 +5,779	+27%	+$564K	0.01%	1533
2021 Q1	$2.19M	Buy	+21,077	New	+$2M	0.01%	1638
2020 Q3	–	Sell	-9,482	Closed	-$362K	–	3422
2020 Q2	$362K	Buy	9,482 +8,832	+1,359%	+$456K	﹤0.01%	2245
2020 Q1	$32K	Buy	+650	New	+$31.9K	﹤0.01%	2955
2019 Q4	–	Sell	-1,045	Closed	-$44K	–	3893
2019 Q3	$44K	Buy	+1,045	New	+$41.1K	﹤0.01%	3356

Other funds holding IMDX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

FOR

Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

John Overdeck's IMDX Position: Q2 2026 in Review

John Overdeck opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 11,101 shares worth $65.5K. The stake represents ﹤0.01% of the portfolio and ranks #4931 among its holdings. This is a return to the name: John Overdeck previously reported a position in IMDX as recently as Q4 2021.

John Overdeck first reported a position in IMDX in Q3 2019 and has held it in 8 quarters since. The position peaked at $3.08M in Q2 2021. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

John Overdeck held 11,101 shares of Insight Molecular Diagnostics worth $65.5K as of Q2 2026.
Insight Molecular Diagnostics was a new John Overdeck position in Q2 2026.
Insight Molecular Diagnostics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4931 holding.
John Overdeck first reported a position in Insight Molecular Diagnostics in Q3 2019 and has held it in 8 quarters since.
John Overdeck's Insight Molecular Diagnostics position peaked at $3.08M in Q2 2021.
40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.